Inhibition of HIV-1 protease by a boron-modified polypeptide. 2000

A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA. pivazya@attglobal.net

Six boronated tetrapeptides with the carboxy moiety of phenylalanine replaced by dihydroxyboron were synthesized, and their activities against human immunodeficiency virus 1 (HIV-1) protease subsequently investigated. The sequences of these peptides were derived from HIV-1 protease substrates, which included the C-terminal part of the scissile bond (Phe-Pro) within the gag-pol polyprotein. Enzymatic studies showed that these compounds were competitive inhibitors of HIV-1 protease with K(i) values ranging from 5 to 18 microM when experiments were performed at high enzyme concentrations (above 5 x 10(-8) M); however, at low protease concentrations inhibition was due in part to an increase of the association constants of the protease subunits. Ac-Thr-Leu-Asn-PheB inhibited HIV-1 protease with a K(i) of 5 microM, whereas the non-boronated parental compound was inactive at concentrations up to 400 microM, which indicates the significance of boronation in enzyme inhibition. The boronated tetrapeptides were inhibitory to an HIV-1 protease variant that is resistant to several HIV-1 protease inhibitors. Finally, fluorescence analysis showed that the interactions between the boronated peptide Ac-Thr-Leu-Asn-PheB and HIV-1 protease resulted in a rapid decrease of fluorescence emission at 360 nm, which suggests the formation of a compound/enzyme complex. Boronated peptides may provide useful reagents for studying protease biochemistry and yield valuable information toward the development of protease dimerization inhibitors.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001896 Boron Compounds Inorganic or organic compounds that contain boron as an integral part of the molecule. Borides,Compounds, Boron
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
January 1997, Biochemical and biophysical research communications,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
April 2008, Chemical biology & drug design,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
November 2006, Antiviral research,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
July 1993, Biochemical and biophysical research communications,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
May 1994, Biochemical and biophysical research communications,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
January 2020, Evidence-based complementary and alternative medicine : eCAM,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
September 1992, Journal of medicinal chemistry,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
February 1995, International immunology,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
February 2001, Journal of the American Chemical Society,
A D Pivazyan, and D S Matteson, and L Fabry-Asztalos, and R P Singh, and P F Lin, and W Blair, and K Guo, and B Robinson, and W H Prusoff
July 2014, Journal of medicinal chemistry,
Copied contents to your clipboard!